Maintenance therapy with subcutaneous immunoglobulin in a patient with immune-mediated neuropathic postural tachycardia syndrome.

Autor:	Pitarokoili K; Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.; Immunmediated Neuropathies Biobank (INHIBIT), Ruhr-University Bochum, Bochum, Germany., Maier A; Department of Neurology, University Clinic Aachen, Germany., de Moya Rubio EC; POTS und andere Dysautonomien e.V. (German Patient Organization, NGO), Bochum, Germany., Hahn K; Department of Neurology and Outpatient Clinic, Charité - University Berlin, Berlin, Germany., Wallukat G; Berlin Cures GmbH, Berlin, Germany., Athanasopoulos D; Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.; Immunmediated Neuropathies Biobank (INHIBIT), Ruhr-University Bochum, Bochum, Germany., Grüter T; Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.; Immunmediated Neuropathies Biobank (INHIBIT), Ruhr-University Bochum, Bochum, Germany., Motte J; Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.; Immunmediated Neuropathies Biobank (INHIBIT), Ruhr-University Bochum, Bochum, Germany., Fisse AL; Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.; Immunmediated Neuropathies Biobank (INHIBIT), Ruhr-University Bochum, Bochum, Germany., Gold R; Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.; Immunmediated Neuropathies Biobank (INHIBIT), Ruhr-University Bochum, Bochum, Germany.
Jazyk:	angličtina
Zdroj:	Journal of translational autoimmunity [J Transl Autoimmun] 2021 Aug 14; Vol. 4, pp. 100112. Date of Electronic Publication: 2021 Aug 14 (Print Publication: 2021).
DOI:	10.1016/j.jtauto.2021.100112
Abstrakt:	Aims: We describe the disease course of a 35-year-old female with an autoimmune mediated neuropathic postural tachycardia syndrome (PoTS), who responded to immunoglobulin therapy and stabilized on maintenance therapy with subcutaneous immunoglobulin (SCIg). Methods: We provide longitudinal data of clinical scores, tilt-table results and antibody titers. Results: Initial treatment with intravenous immunoglobulin caused infusion-related side-effects whereas SCIg was well tolerated and improved clinical symptoms and quality of life. Clinical improvement correlated with the reduction of serum antibody titers 22 months after first infusion. Conclusions: These findings suggest that autoimmune-mediated neuropathic PoTS can be treated sufficiently with IVIg whereas SCIg minimizes side-effects. (© 2021 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu